Infectious Disease and Vaccine
Our experts stand ready to help you fight against outbreaks by studying the effectiveness of your therapies.
Our experts stand ready to help you fight against outbreaks by studying the effectiveness of your therapies.
Allucent is ready to partner with you to conduct trials for infectious diseases caused by viruses, bacteria, fungi, or parasites. We’ve been part of the effort against COVID-19, and our extensive experience
provides a significant advantage in proven strategic planning, regulatory guidance, and successful clinical trial execution.
We are particularly experienced in working on government-funded infectious disease and vaccine trials, and were selected by the U.S. Department of Defense as a prime CRO contractor for the Operation Warp Speed effort against COVID-19.
It’s important to choose a team that has the right kind of therapeutic experience for your clinical trial. Allucent’s therapeutically aligned, specialized staff have a broad range of expertise in infectious disease and vaccine clinical development and regulations from the U.S., EU, and beyond.
Our vaccines development experts have extensive experience designing, implementing, and executing clinical trials involving live attenuated, inactivated, subunit, toxoid, mRNA, and viral vector vaccines for infectious diseases, allergies, immunotherapies, and oncology indications. These include COVID-19, hepatitis B & C, grass, birch, and dust mite allergies, cervical cancer, and melanoma.
Data-driven, risk-based monitoring solutions, including centralized monitoring, are designed specifically to manage large data volumes upon enrollment of vaccine trials, while ensuring data integrity in remote settings.
Natural selection of pathogens, diversity of trial participants, and timing are all important site-selection criteria for infectious disease clinical trials. Our global reach, including industry-leading Central and Eastern Europe specialization, provides access to patient populations, site networks, and academic institutions, focused on meeting and exceeding your enrollment goals.
Allucent's teams have deep expertise in supporting studies in an ICU/critical care setting and navigating the common challenges encountered in this complex environment. That knowledge enables us to provide proactive and insightful CRO services based on proven strategies for indications from pneumonia to COVID-19.
We have supported federally funded vaccine and infectious disease clinical research programs for more than 20 years. Our proven track record has allowed us to collaborate with multiple government agencies including NIH, DOD, BARDA, and CDC.
Whether your new product is a drug, vaccine, biologic, GMO, cell and gene therapy, device, or a combination product, we understand the nuances of regulatory requirements and have the resources and proven expertise to address your specific needs.
Allucent stands with the global community in the fight against COVID-19. No other disease in recent history has captured the world like Coronavirus. We are poised to help pharmaceutical and biotechs by rapidly deploying their clinical trials in the search for vaccines and therapies to fight infectious disease.
We have several ongoing COVID-19 studies and are proud to have been selected by the U.S. Department of Defense as a prime CRO contractor in support of Operation Warp Speed. We continue these efforts through ongoing activities in support of its successor, the Countermeasures Acceleration Group (CAG).
We understand that drug development partners with medical countermeasures (MCM) expertise are crucial in bringing vaccines and treatments to the front lines of the COVID-19 battle. As an MCM-capable CRO, Allucent has the full capabilities to support your initiative.
Allucent currently holds memberships in the Medical CBRN Defense Consortium (MCDC). We also work with the DoD's Other Transaction Authority (OTA) and under Other Transactions (OTs).